


## Oxethazaine

Cat. No.:	HY-B0955
CAS No.:	126-27-2
Molecular Formula:	C <sub>28</sub> H <sub>41</sub> N <sub>3</sub> O <sub>3</sub>
Molecular Weight:	467.64
Target:	HBV
Pathway:	Anti-infection
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    6 months -20°C    1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (106.92 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1384 mL	10.6920 mL	21.3840 mL
	5 mM		0.4277 mL	2.1384 mL	4.2768 mL
	10 mM		0.2138 mL	1.0692 mL	2.1384 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: 2.5 mg/mL (5.35 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistant and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis<sup>[1]</sup>.

#### In Vivo

Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its positive control group phentermine only 3 mg/kg causes significant CPP<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats <sup>[1]</sup>
Dosage:	5, 10, and 15 mg/kg; during days 4–11
Administration:	Intraperitoneal injection
Result:	Showed a significant CPP in vivo.

## CUSTOMER VALIDATION

- Stem Cell Res Ther. 2021 Feb 4;12(1):107.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. SEIFTER J, ET AL. Oxethazaine and related congeners: a series of highly potent local anesthetics. Proc Soc Exp Biol Med. 1962 Mar;109:664-8.

[2]. Soo-Yeun Lee, et al. The abuse potential of oxethazaine: Effects of oxethazaine on drug-seeking behavior and analysis of its metabolites in plasma and hair in animal models. Pharmacology, Biochemistry and Behavior

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA